Functional MRI for radiotherapy dose painting

Magnetic Resonance Imaging

Volumn 30, Issue 9, 2012, Pages 1216-1223

  van der Heide, Uulke A ^a   Houweling, Antonetta C ^a   Groenendaal, Greetje ^a   Beets Tan, Regina G H ^b   Lambin, Philippe ^b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

DCE MRI; Dose painting; DWI; Radiation oncology

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BLOOD FLOW; BLOOD VESSEL PERMEABILITY; CANCER RADIOTHERAPY; CELL DENSITY; DIFFUSION WEIGHTED IMAGING; DRUG DOSE ESCALATION; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MICROVASCULATURE; OXYGENATION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE PAINTING; RADIATION EXPOSURE; RADIOSENSITIVITY; TUMOR VOLUME;

BREAST NEOPLASMS; DIAGNOSTIC IMAGING; DOSE FRACTIONATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICROCIRCULATION; NEOPLASMS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS;

EID: 84867143134     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2012.04.010     Document Type: Article

References (78)

1. Mageras G.S., Mechalakos J. Planning in the IGRT context: closing the loop. Semin Radiat Oncol 2007, 17:268-277.
2. Bujold A., Craig T., Jaffray D., Dawson L. Image-guided radiotherapy: has it influenced patient outcomes?. Semin Radiat Oncol 2012, 22:50-61.
3. Haie-Meder C., Siebert F.A., Pötter R. Image guided, adaptive, accelerated, high dose brachytherapy as model for advanced small volume radiotherapy. Radiother Oncol 2011, 100:333-343.
4. Tanderup K., Georg D., Pötter R., Kirisits C., Grau C., Lindegaard J.C. Adaptive management of cervical cancer radiotherapy. Semin Radiat Oncol 2010, 20:121-129.
5. De Neve W., De Gersem W., Madani I. Rational use of intensity-modulated radiation therapy: the importance of clinical outcome. Semin Radiat Oncol 2012, 22:40-49.
6. Ling C.C., Humm J., Larson S., Amols H., Fuks Z., Leibel S., et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000, 47:551-560.
7. Bentzen S.M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005, 6:112-117.
8. Thorwarth D., Eschmann S.M., Paulsen F., Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 2007, 68:291-300.
9. Bowen S.R., Flynn R.T., Bentzen S.M., Jeraj R. On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. Phys Med Biol 2009, 54:1483-1501.
10. Petit S.F., Dekker A.L.A.J., Seigneuric R., Murrer L., van Riel N.A.W., Nordsmark M., et al. Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study. Phys Med Biol 2009, 54:2179-2196.
11. Aerts H.J.W.L., van Baardwijk A.A.W., Petit S.F., Offermann C., van Loon J., Houben R., et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009, 91:386-392.
12. Aerts H.J.W.L., Bussink J., Oyen W.J.G., van Elmpt W., Folgering A.M., Emans D., et al. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer 2012, 75:73-76.
13. Malinen E., Søvik A., Hristov D., Bruland Ø.S., Olsen D.R. Adapting radiotherapy to hypoxic tumours. Phys Med Biol 2006, 51:4903-4921.
14. van Loon J., Janssen M.H.M., Ollers M., Aerts H.J.W.L., Dubois L., Hochstenbag M., et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging 2010, 37:1663-1668.
15. Lambin P., Petit S.F., Aerts H.J.W.L., van Elmpt W.J.C., Oberije C.J.G., Starmans M.H.W., et al. Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother Oncol 2010, 96:145-152.
16. Dubois L.J., Lieuwes N.G., Janssen M.H.M., Peeters W.J.M., Windhorst A.D., Walsh J.C., et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A 2011, 108:14620-14625.
17. van den Bogaard J., Janssen M.H.M., Janssens G., Buijsen J., Reniers B., Lambin P., et al. Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer. Radiother Oncol 2011, 99:137-141.
18. Madani I., Duthoy W., Derie C., De Gersem W., Boterberg T., Saerens M., et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 68:126-135.
19. Duprez F., De Neve W., De Gersem W., Coghe M., Madani I. Adaptive dose painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011, 80:1045-1055.
20. PET Boost trial. Dose escalation by boosting radiation dose within the primary tumor on the basis of a pre-treatment FDG-PET-CT scan in stage IB, II and III NSCLC: a randomized Phase II trial. ctgov:NCT01024829.
21. Padhani A.R., Liu G., Koh D.M., Chenevert T.L., Thoeny H.C., Takahara T., et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009, 11:102-125.
22. Brix G., Griebel J., Kiessling F., Wenz F. Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nucl Med Mol Imaging 2010, 37:S30-S51.
23. Padhani A.R., Khan A.A. Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Target Oncol 2010, 5:39-52.
24. Turkbey B., Pinto P.A., Mani H., Bernardo M., Pang Y., McKinney Y.L., et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection - histopathologic correlation. Radiology 2010, 255:89-99.
25. Buijsen J., van den Bogaard J., Janssen M.H.M., Bakers F.C.H., Engelsman S., Öllers M., et al. FDG-PET provides the best correlation with the tumor specimen compared to MRI and CT in rectal cancer. Radiother Oncol 2011, 98:270-276.
26. Groenendaal G., van den Berg C.A.T., Korporaal J.G., Philippens M.E.P., Luijten P.R., van Vulpen M., et al. Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiother Oncol 2010, 95:185-190.
27. Vos P.C., Hambrock T., Hulsbergen-van de Kaa C.A., Fütterer J.J., Barentsz J.O., Huisman H.J. Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. Med Phys 2008, 35:888-899.
28. 2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009, 30:327-334.
29. Ozer S., Langer D.L., Liu X., Haider M.A., van der Kwast T.H., Evans A.J., et al. Supervised and unsupervised methods for prostate cancer segmentation with multispectral MRI. Med Phys 2010, 37:1873-1883.
30. Groenendaal G., Borren A., Moman M.R., Monninkhof E., van Diest P.J., Philippens M.E., et al. Pathologic validation of a model based on diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging for tumor delineation in the prostate peripheral zone. Int J Radiat Oncol Biol Phys 2012, 82:e537-e544.
31. van Vulpen M., van den Berg C.A.T., Moman M.R., van der Heide U.A. Difficulties and potential of correlating local recurrences in prostate cancer with the delivered local dose. Radiother Oncol 2009, 93:180-184.
32. Verduijn G.M., Bartels L.W., Raaijmakers C.P., Terhaard C.H., Pameijer F.A., van den Berg C.A. Magnetic resonance imaging protocol optimization for delineation of gross tumor volume in hypopharyngeal and laryngeal tumors. Int J Radiat Oncol Biol Phys 2009, 74:630-636.
33. Siegler P., Holloway C.M.B., Causer P., Thevathasan G., Plewes D.B. Supine breast MRI. J Magn Reson Imaging 2011, 34:1212-1217.
34. Haie-Meder C., Pötter R., Van Limbergen E., Briot E., De Brabandere M., Dimopoulos J., et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005, 74:235-245.
35. Villeirs G.M., Verstraete K.L., De Neve W.J., De Meerleer G.O. Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother Oncol 2005, 76:99-106.
36. McLaughlin P.W., Troyer S., Berri S., Narayana V., Meirowitz A., Roberson P.L., et al. Functional anatomy of the prostate: implications for treatment planning. Int J Radiat Oncol Biol Phys 2005, 63:479-491.
37. Khoo V.S., Padhani A.R., Tanner S.F., Finnigan D.J., Leach M.O., Dearnaley D.P. Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. Br J Radiol 1999, 72:590-597.
38. Sumanaweera T.S., Glover G.H., Binford T.O., Adler J.R. MR susceptibility misregistration correction. IEEE Trans Med Imaging 1993, 12:251-259.
39. Chang H., Fitzpatrick J.M. A technique for accurate magnetic resonance imaging in the presence of field inhomogeneities. IEEE Trans Med Imaging 1992, 11:319-329.
40. Bakker C.J.G., Moerland M.A., Bhagwandien R., Beersma R. Analysis of machine-dependent and object-induced geometric distortions in 2DFT MR imaging. Magn Reson Imaging 1992, 10:597-608.
41. Moerland M.A., Beersma R., Bhagwandien R., Wijrdeman H.K., Bakker C.J.G. Analysis and correction of geometric distortions in 1.5 T magnetic resonance images for use in radiotherapy treatment planning. Phys Med Biol 1995, 40:1651-1664.
42. Reinsberg S.A., Doran S.J. A complete distortion correction for MR images: II. Rectification of static-field inhomogeneities by similarity-based profile mapping. Phys Med Biol 2005, 50:2651-2661.
43. Zhang B., MacFadden D., Damyanovich A.Z., Rieker M., Stainsby J., Bernstein M., et al. Development of a geometrically accurate imaging protocol at 3 Tesla MRI for stereotactic radiosurgery treatment planning. Phys Med Biol 2010, 55:6601-6615.
44. MacFadden D., Zhang B., Brock K.K., Hodaie M., Laperriere N., Schwartz M., et al. Clinical evaluation of stereotactic target localization using 3-Tesla MRI for radiosurgery planning. Int J Radiat Oncol Biol Phys 2010, 76:1472-1479.
45. Haack S., Nielsen S.K., Lindegaard J.C., Gelineck J., Tanderup K. Applicator reconstruction in MRI 3D image-based dose planning of brachytherapy for cervical cancer. Radiother Oncol 2009, 91:187-193.
46. 0 field variations. Magn Reson Med 1995, 34:65-73.
47. Nestle U., Kremp S., Schaefer Schuler A., Sebastian Welsch C., Hellwig D., Rübe C., et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 2005, 46:1342-1348.
48. Geets X., Lee J.A., Bol A., Lonneux M., Grégoire V. A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging 2007, 34:1427-1438.
49. Schaefer A., Kremp S., Hellwig D., Rübe C., Kirsch C.M., Nestle U. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging 2008, 35:1989-1999.
50. Lee J.A. Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother Oncol 2010, 96:302-307.
51. Lambregts D.M., Beets G.L., Maas M., Curvo-Semedo L., Kessels A.G., Thywissen T., et al. Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability. Eur Radiol 2011, 12:2567-2574.
52. Gibbs P., Pickles M.D., Turnbull L.W. Repeatability of echo-planar-based diffusion measurements of the human prostate at 3 T. Magn Reson Imaging 2007, 25:1423-1429.
53. 1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10:223-232.
54. van Dorsten F.A., van der Graaf M., Engelbrecht M.R.W., van Leenders G.J.L.H., Verhofstad A., Rijpkema M., et al. Combined quantitative dynamic contrast-enhanced MR imaging an 1H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004, 20:279-287.
55. 1-weighted MR imaging - initial experience. Radiology 2004, 233:709-715.
56. Kozlowski P., Chang S.D., Jones E.C., Berean K.W., Chen H., Goldenberg S.L. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis - correlation with biopsy and histopathology. J Magn Reson Imaging 2006, 24:108-113.
57. Ocak I., Bernardo M., Metzger G., Barrett T., Pinto P., Albert P.S., et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Am J Roentgenol 2007, 189:849.
58. Alonzi R., Taylor N.J., Stirling J.J., d'Arcy J.A., Collins D.J., Saunders M.I., et al. Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. J Magn Reson Imaging 2010, 32:155-164.
59. Kozlowski P., Chang S.D., Meng R., Mädler B., Bell R., Jones E.C., et al. Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T - quantitative correlation with biopsy. Magn Reson Imaging 2010, 28:621-628.
60. 2, K(trans), v(e), and corresponding histologic features. Radiology 2010, 255:485-494.
61. Korporaal J.G., van den Berg C.A.T., Jeukens C.R.L.P.N., Groenendaal G., Moman M.R., Luijten P., et al. Dynamic contrast-enhanced CT for prostate cancer: relationship between image noise, voxel size, and repeatability. Radiology 2010, 256:976-984.
62. Linskey M.E. Hearing preservation in vestibular schwannoma stereotactic radiosurgery: what really matters?. J Neurosurg 2008, 109(Suppl.):129-136.
63. Singh A.K., Guion P., Sears-Crouse N., Ullman K., Smith S., Albert P.S., et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol 2007, 2:36.
64. Fonteyne V., Villeirs G., Speleers B., De Neve W., De Wagter C., Lumen N., et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008, 72:799-807.
65. Cellini N., Morganti A.G., Mattiucci G.C., Valentini V., Leone M., Luzi S., et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002, 53:595-599.
66. Pucar D., Hricak H., Shukla-Dave A., Kuroiwa K., Drobnjak M., Eastham J., et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 2007, 69:62-69.
67. Lips I.M., van der Heide U.A., Haustermans K., van Lin E.N.J.T., Pos F., Franken S.P.G., et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials 2011, 12:255.
68. Laprie A., Catalaa I., Cassol E., McKnight T.R., Berchery D., Marre D., et al. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys 2008, 70:773-781.
69. Thorwarth D., Henke G., Müller A.C., Reimold M., Beyer T., Boss A., et al. Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience. Int J Radiat Oncol Biol Phys 2011, 81:277-283.
70. Lambrecht M., Vandecaveye V., De Keyzer F., Roels S., Penninckx F., Van Cutsem E., et al. Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. Int J Radiat Oncol Biol Phys 2012, 82:863-870.
71. Curvo-Semedo L., Lambregts D.M., Maas M., Thywissen T., Mehsen R.T., Lammering G., et al. Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy - conventional MR volumetry versus diffusion-weighted MR imaging. Radiology 2011, 260:734-743.
72. Lambregts D.M., Vandecaveye V., Barbaro B., Bakers F.C., Lambrecht M., Maas M., et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol 2011, 18:2224-2231.
73. Mayr N.A., Yuh W.T., Magnotta V.A., Ehrhardt J.C., Wheeler J.A., Sorosky J.I., et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys 1996, 36:623-633.
74. Stewart J., Lim K., Kelly V., Xie J., Brock K.K., Moseley J., et al. Automated weekly replanning for intensity-modulated radiotherapy of cervix cancer. Int J Radiat Oncol Biol Phys 2010, 78:350-358.
75. Lagendijk J.J.W., Raaymakers B.W., Raaijmakers A.J.E., Overweg J., Brown K.J., Kerkhof E.M., et al. MRI/linac integration. Radiother Oncol 2008, 86:25-29.
76. Raaymakers B.W., Lagendijk J.J.W., Overweg J., Kok J.G.M., Raaijmakers A.J.E., Kerkhof E.M., et al. Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept. Phys Med Biol 2009, 54:N229-N237.
77. Raaymakers B.W., Raaijmakers A.J.E., Lagendijk J.J.W. Feasibility of MRI guided proton therapy: magnetic field dose effects. Phys Med Biol 2008, 53:5615-5622.
78. Dimopoulos J.C., Schmid M.P., Fidarova E., Berger D., Kirisits C., Pötter R. Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results. Int J Radiat Oncol Biol Phys 2012, 82:1880-1888.